CliffBio
small molecule

TARKA

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameTARKA
Active ingredientTRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE
Strength2MG;240MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 1996
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TARKA patent cliff — loss of exclusivity — | CliffBio